Topical immunomodulators are effective for treatment of vitiligo

Journal of Dermatology

Volumn 35, Issue 8, 2008, Pages 503-507

  Choi, Chong Won ^b   Chang, Sung Eun ^c   Bak, Hana ^c   Choi, Jee Ho ^c   Park, Hyun Sun ^b   Huh, Chang Hun ^b   Kim, Chan Woong ^d   Kim, Sung Eun ^d   Mun, Seog Kyun ^d   Kim, Beom Joon ^a,d   Kim, Myeung Nam ^d  

^a Seoul National University Bundang Hospital ^*  (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Steroid; Topical immunomodulator; Vitiligo

Indexed keywords

IMMUNOMODULATING AGENT; PIMECROLIMUS; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OINTMENT; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SKIN PIGMENTATION; TREATMENT OUTCOME; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OINTMENTS; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; VITILIGO;

EID: 49349096557     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2008.00511.x     Document Type: Article

References (33)

1. Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 51 : 52 61.
2. Al'Abadie MS, Senior HJ, Bleehen SS et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994 131 : 160 165.
3. Bystryn JC. Immune mechanisms in vitiligo. Clin Dermatol 1997 15 : 853 861.
4. Lerner AB. On the etiology of vitiligo and gray hair. Am J Med 1971 51 : 141 147.
5. Nordlund JJ, Majumder PP. Recent investigations on vitiligo vulgaris. Dermatol Clin 1997 15 : 69 78.
6. Silverberg NB, Lin P, Travis L et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004 51 : 760 766.
7. Norris DA, Kissinger RM, Naughton GM et al. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988 90 : 783 789.
8. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986 15 : 978 981.
9. Lan CC, Chen GS, Chiou MH et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005 153 : 498 505.
10. Ivanova K, Le Poole IC, Gerzer R et al. Effect of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol 1997 183 : 469 476.
11. Jimbow K, Chen H, Park JS et al. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001 144 : 55 65.
12. Fitzpatrick TB. Mechanisms of phototherapy of vitiligo. Arch Dermatol 1997 133 : 1591 1592.
13. Mandel AS, Haberman HF, Pawlowski D et al. Non PUVA nonsurgical therapies for vitiligo. Clin Dermatol 1997 15 : 907 919.
14. Njoo MD, Spuls PI, Bos JD et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998 134 : 1532 1540.
15. Grimes PE, Ghoneum M, Stockton T et al. T cell profiles in vitiligo. J Am Acad Dermatol 1986 14 : 196 201.
16. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001 44 : S28 S38.
17. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005 65 : 447 459.
18. Luger T, Van Leent EJ, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 144 : 788 794.
19. Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997 337 : 816 821.
20. Van Leent EJ, Graber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998 134 : 805 809.
21. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 144 : 507 513.
22. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998 111 : 396 398.
23. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002 47 : 789 791.
24. Lepe V, Moncada B, Castanedo-Cazares JP et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 139 : 581 585.
25. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003 71 : 158 162.
26. Mayoral FA, Gonzalez C, Shah NS et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003 207 : 322 323.
27. Tjioe M, Vissers WH, Gerritsen MJ. Topical macrolide immunomodulators: a role in the treatment of vitiligo? Am J Clin Dermatol 2006 7 : 7 12.
28. Bartosik J, Wulf HC, Kobayasi T. Melanin and melanosome complexes in long standing stable vitiligo-an ultrastructural study. Eur J Dermatol 1998 8 : 95 97.
29. Galadari E, Mehregan AH, Hashimoto K. Ultrastructural study of vitiligo. Int J Dermatol 1993 32 : 269 271.
30. Brown J, Winklemann RK, Wolff K. Langerhans cells in vitiligo: a qualitative study. J Invest Dermatol 1967 49 : 386 390.
31. Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983 10 : 207 212.
32. Tobin DJ, Swanson NN, Pittelkow MR et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000 191 : 407 416.
33. Grimes PE. Vitiligo. An overview of therapeutic approaches. Dermatol Clin 1993 11 : 325 338.